At 5.7% CAGR, the North America Acute Pancreatitis Market is projected to be worth US$ 5,000.71 million by 2030, says Business Market Insights

According to Business Market Insights’ research, the North America acute pancreatitis market was valued at US$ 3,209.63 million in 2022 and is expected to reach US$ 5,000.71 million by 2030, registering a CAGR of 5.7% from 2022 to 2030. Rise in pancreatic cancer cases due to acute pancreatitis, rising incidence of diabetes following acute pancreatitis, and advancements in specific acute pancreatitis treatments are among the critical factors attributed to the North America acute pancreatitis market expansion.  

Acute pancreatitis is an inflammatory disorder of the pancreas. The condition is associated with increased morbidity and mortality because there is no specific treatment approved to treat it, leaving supportive care as the main course of treatment. A targeted novel treatment strategy that halts disease progression and improves patient outcomes is needed to address the current disease burden of acute and severe acute pancreatitis. An article published in the National Library of Medicine in February 2023 focuses on 3 major approaches to advance acute pancreatitis treatments—the clinical identification and application of new genetic information; newly identified serum biomarkers, i.e., fatty acid ethyl esters (FAEEs); and acceleration in timing of early nutrition feedings in acute pancreatitis. Clinical Identification and Application of New Genetic Information: When acute pancreatitis occurs at the age of 35 years or when it is relapsing or idiopathic, testing for the 6 commercially evaluable genetic causes of acute pancreatitis is recommended. This test provides valuable information regarding the diagnosis probability of genetic predisposition, cofactors that are likely to play a role in disease identification and a suitable approach to initiate treatment early in the process, without requiring repeated testing. Newly Identified Serum Biomarkers—FAEEs: During a prospective, blinded trial, researchers compared the levels of FAEE, nonesterified fatty acids, and ethanol in the blood of 175 patients hospitalized for alcoholic pancreatitis, alcohol intoxication, nonalcoholic pancreatitis, and normal controls. This test has the unique capability of demonstrating diagnostic elevations of FAEEs associated with alcohol consumption. Therefore, it can be evaluated that alcohol is the cause of alcohol-associated pancreatitis and to exclude it when there are other causes. Important Acceleration in Timing of Early Feedings in Acute Pancreatitis: The practice of beginning early feeding through the nasogastric/nasojejunal routes after the onset of acute pancreatitis has been supported by multiple randomized controlled trials and has replaced the practice of resting the gastrointestinal tract until pain subsides prior to feeding. This approach results in increased bowel motility and reduced organ failure, infection, length of stay, and mortality rates, confirming that an idle intestine leads to bacterial overgrowth, increased permeability, and bacterial translocation. Such developments in specific treatment approaches would lead to new treatment options to enhance outcomes and improve the North America acute pancreatitis market in the near future.

On the contrary, side effects of pancreatitis and pancreatic cancer treatments hampers on the growth of North America acute pancreatitis market. 

Based on offerings, the North America acute pancreatitis market is segmented into medications, diagnosis, and others. The diagnosis segment held 56.6% share of North America acute pancreatitis market in 2022, amassing US$ 1,817.69 million. It is projected to garner US$ 2,805.77 million by 2030 to expand at 5.6% CAGR during 2022–2030.

Based on causes, the North America acute pancreatitis market is segmented into gallstones, alcoholism, genetic disorders, infection, and others. The gallstones segment held 45.7% share of North America acute pancreatitis market in 2022, amassing US$ 1,467.54 million. It is projected to garner US$ 2,354.55 million by 2030 to expand at 6.1% CAGR during 2022–2030.

Based on end user, the North America acute pancreatitis market is divided into hospitals, diagnostic laboratories, ambulatory surgical centres, and others. The hospitals segment held 75.4% share of North America acute pancreatitis market in 2022, amassing US$ 2,419.26 million. It is projected to garner US$ 3,745.25 million by 2030 to expand at 5.6% CAGR during 2022–2030.

Based on country, the North America acute pancreatitis market has been categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 89.7% share of North America acute pancreatitis market in 2022. It was assessed at US$ 2,879.68 million in 2022 and is likely to hit US$ 4,450.63 million by 2030, exhibiting a CAGR of 5.6% during 2022–2030.            

Key players operating in the North America acute pancreatitis market are Abbott Laboratories, Baxter International Inc, Boston Scientific Corp, Dynavax Technologies Corp, Fresenius Kabi AG, GE HealthCare Technologies Inc, Koninklijke Philips NV, Medtronic Plc, and Samsung Healthcare, among others.

• In May 2023, GE HealthCare announced US FDA 510(k) clearance of Precision DL – a new, revolutionary deep learning-based image processing software included in GE HealthCare’s growing Effortless Recon DL portfolio. Precision DL provides the image quality performance benefits typically associated with hardware-based Time-of-Flight (ToF) reconstruction, including improved contrast-to-noise ratio, contrast recovery, and quantitative accuracy.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com